Search

China eliminated rural poverty under current poverty standards in 2020. However, compared with rural poverty, urban poverty in China has been somewhat neglected. This paper aims to discover the changes and determinants of multidimensional urban poverty in Shandong Province, a representative province in Eastern China. Using a nationally representative panel dataset, the China Family Panel Studies, and the Dual Cutoff method, this study creates a multidimensional poverty index with four dimensions and 11 indicators to measure urban poverty in Shandong Province. This paper discovers that while the incidence of multidimensional urban poverty in Shandong Province decreased from 47.62% in 2010 to 36.45% in 2018, the intensity of multidimensional poverty only decreased from 41.27% to 37.25%, which indicates the inadequacy of urban anti-poverty efforts in Shandong Province. This paper also uses logistic regression to identify the determinants of multidimensional urban poverty. The findings suggest that income, health, drinking water, and durable goods are the main determinants of multidimensional urban poverty in Shandong Province. Based on these findings, this study provides targeted recommendations for future urban anti-poverty policies in Shandong Province. [ABSTRACT FROM AUTHOR]

Background: In November 2015, China launched a pilot program for its Drug Marketing Authorization Holder (MAH) system, aiming to integrate production and research and development resources to spur drug innovation. While many scholars have examined the theoretical relationship between the MAH system and pharmaceutical manufacturing innovation, empirical studies have been scarce. Methods: This study uses inter-provincial panel data on China's pharmaceutical manufacturing industry from 2009 to 2019, along with synthetic control methods, to offer a robust analysis of the impact of the MAH paradigm on innovation quality in pilot provinces. We treat the 2015 MAH system implementation in ten provinces as a natural experiment and account for the mediating effects of R&D investments, allowing us to discern the underlying mechanisms. Results: Our findings demonstrate a significant positive effect of China's MAH system on innovation quality in the pharmaceutical manufacturing industry. Specifically, the system is most effective in Jiangsu, Guangdong, and Shandong provinces. We also identify R&D investments as playing a mediating role in facilitating the favorable impact of the MAH system on innovation quality. Conclusion: Our study highlights the crucial importance of the MAH system in promoting innovation quality in China's pharmaceutical manufacturing industry, providing vital empirical support for its adoption and further enhancement. This research also offers practical insights for policymakers and R&D decision-makers in the pharmaceutical sector. [ABSTRACT FROM AUTHOR]